Whither vaccines?

Journal of Infection

Volumn 74, Issue , 2017, Pages S2-S9

  Rodrigues, Charlene M C ^a   Pinto, Marta V ^b   Sadarangani, Manish ^b,c   Plotkin, Stanley A ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CMV; Dengue; HIV; Host immunity; Influenza; Pertussis; Rotavirus; RSV; Structural biology; Vaccinology

Indexed keywords

ACELLULAR VACCINE; CYTOMEGALOVIRUS VACCINE; DENGUE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; PERTUSSIS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

ARTICLE; CYTOMEGALOVIRUS INFECTION; DENGUE HEMORRHAGIC FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSENESCENCE; MICROBIAL IMMUNITY; MICROBIOME; NONHUMAN; PERTUSSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; ROTAVIRUS INFECTION; SEASONAL INFLUENZA; SYSTEMS BIOLOGY; VACCINATION; VACCINE IMMUNOGENICITY; VACCINE PRODUCTION; COMMUNICABLE DISEASE; DRUG DEVELOPMENT; ECONOMICS; FINANCIAL MANAGEMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; TECHNOLOGY; TRENDS;

CAPITAL FINANCING; COMMUNICABLE DISEASES; DRUG DISCOVERY; HUMANS; TECHNOLOGY TRANSFER; VACCINES;

EID: 85026212979     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/S0163-4453(17)30184-6     Document Type: Article

References (84)

1. Baxby, D., Edward Jenner's inquiry after 200 years. BMJ, 318(7180), 1999, 390.
2. Giuliani, M.M., Adu-Bobie, J., Comanducci, M., Arico, B., Savino, S., Santini, L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103:29 (2006), 10834–10839.
3. Pica, N., Palese, P., Toward a Universal Influenza Virus Vaccine: Prospects and Challenges. Annu Rev Med 64:1 (2013), 189–202.
4. Manzoli, L., loannidis, J.P.A., Flacco, M.E., De Vito, C., Villari, P., Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly. Hum Vaccin Immunother 8:7 (2012), 851–862.
5. DiazGranados, C.A., Denis, M., Plotkin, S., Seasonal influenza vaccine efficacy and its determinants in children and nonelderly adults: A systematic review with meta-analyses of controlled trials. Vaccine 31:1 (2012), 49–57.
6. Schotsaert, M., García-Sastre, A., Influenza Vaccines: A Moving Interdisciplinary Field. Viruses 6:10 (2014), 3809–3826.
7. Hensley, S.E., Das, S.R., Bailey, A.L., Schmidt, L.M., Hickman, H.D., Jayaraman, A., et al. Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift. Science 326:5953 (2009), 734–736.
8. McElhaney, J.E., Coler, R.N., Baldwin, S.L., Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 12:7 (2013), 759–766.
9. Ambrose, C.S., Levin, M.J., Belshe, R.B., The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 5:2 (2010), 67–75.
10. Novartis Vaccines and Diagnostics Inc. FLUAD® (Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1), Product Monograph. 2014.
11. National Advisory Committee on Immunization. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2015–2016. 2015, Public Health Agency of Canada, Canada.
12. Zedda, L., Forleo-Neto, E., Vertruyen, A., Raes, M., Marchant, A., Jansen, W., et al. Dissecting the Immune Response to MF59-adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age. Pediatr Infect Dis J 34:1 (2015), 73–78.
13. Frey, S.E., Reyes, M.R.A., Reynales, H., Bermal, N.N., Nicolay, U., Narasimhan, V., et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32:39 (2014), 5027–5034.
14. Plotkin, S.A., Increasing Complexity of Vaccine Development. J Infect Dis 212:suppl 1 (2015), S12–S16.
15. World Health Organisation. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 40:85 (2010), 385–400.
16. Kmietowicz, Z., Pertussis cases rise 10-fold among older children and adults in England and Wales. BMJ 345:jul23 1 (2012), e5008–e.
17. de Greeff, S.C., de Melker, H.E., vanGageldonk, P.G.M., Schellekens, J.F.P., van derKlis, F.R.M., Mollema, L., et al. Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis. PLoS One, 5(12), 2010, e14183.
18. Lee Grace, M., Lett, S., Schauer, S., LeBaron, C., Murphy Trudy, V., Rusinak, D., et al. Societal Costs and Morbidity of Pertussis in Adolescents and Adults. Clin Infect Dis 39:11 (2004), 1572–1580.
19. Koepke, R., Eickhoff, J.C., Ayele, R.A., Petit, A.B., Schauer, S.L., Hopfensperger, D.J., et al. Estimating the Effectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) for Preventing Pertussis: Evidence of Rapidly Waning Immunity and Difference in Effectiveness by Tdap Brand. J Infect Dis 210:6 (2014), 942–953.
20. Allen, A.C., Mills, K.H.G., Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev Vaccines 13:10 (2014), 1253–1264.
21. Warfel, J.M., Merkel, T.J., The baboon model of pertussis: effective use and lessons for pertussis vaccines. Expert Rev Vaccines 13:10 (2014), 1241–1252.
22. Warfel, J.M., Zimmerman, L.I., Merkel, T.J., Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 111:2 (2014), 787–792.
23. Rathore, J.S., Wang, Y., Protective role of Th17 cells in pulmonary infection. Vaccine 34:13 (2016), 1504–1514.
24. Lam, C., Octavia, S., Bahrame, Z., Sintchenko, V., Gilbert, G.L., Lan, R., Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol 12:2 (2012), 492–495.
25. Sealey, K.L., Harris, S.R., Fry, N.K., Hurst, L.D., Gorringe, A.R., Parkhill, J., et al. Genomic Analysis of Isolates From the United Kingdom 2012 Pertussis Outbreak Reveals That Vaccine Antigen Genes Are Unusually Fast Evolving. J Infect Dis 212:2 (2014), 294–301.
26. Sebo, P., Osicka, R., Masin, J., Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines. Expert Rev Vaccines 13:10 (2014), 1215–1227.
27. Fedele, G., Bianco, M., Ausiello, C.M., The Virulence Factors of Bordetella pertussis: Talented Modulators of Host Immune Response. Arch Immunol Ther Exp 61:6 (2013), 445–457.
28. Thorstensson, R., Trollfors, B., Al-Tawil, N., Jahnmatz, M., Bergström, J., Ljungman, M., et al. A Phase I Clinical Study of a Live Attenuated Bordetella pertussis Vaccine – BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers. PLoS One, 9(1), 2014, e83449.
29. Li, Q.T., Zhu, Y.Z., Chu, J.Y., Dong, K., He, P., Feng, C.Y., et al. Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine. Acta Pharmacol Sin 27:11 (2006), 1487–1494.
30. Maartens, G., Celum, C., Lewin, S.R., HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384:9939 (2014), 258–271.
31. Lihana, R.W., Ssemwanga, D., Abimiku, A., Ndembi, N., Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev 14:2 (2012), 83–100.
32. Kim, J.H., Excler, J.L., Michael, N.L., Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66 (2015), 423–437.
33. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:23 (2009), 2209–2220.
34. Yates, N.L., Liao, H.X., Fong, Y., deCamp, A., Vandergrift, N.A., Williams, W.T., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med, 6(228), 2014, 228ra39.
35. Excler, J.L., Ake, J., Robb, M.L., Kim, J.H., Plotkin, S.A., Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol 21:8 (2014), 1023–1036.
36. Jegaskanda, S., Weinfurter, J.T., Friedrich, T.C., Kent, S.J., Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques. J Virol 87:10 (2013), 5512–5522.
37. Jegaskanda, S., Luke, C., Hickman, H.D., Sangster, M.Y., Wieland-Alter, W.F., McBride, J.M., et al. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. J Infect Dis 214:6 (2016), 945–952.
38. Hansen, S.G., Piatak, M. Jr., Ventura, A.B., Hughes, C.M., Gilbride, R.M., Ford, J.C., et al. Immune clearance of highly pathogenic SIV infection. Nature 502:7469 (2013), 100–104.
39. Dennehy, P.H., Rotavirus vaccines: an overview. Clin Microbiol Rev 21:1 (2008), 198–208.
40. Bishop, R.F., Barnes, G.L., Cipriani, E., Lund, J.S., Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 309:2 (1983), 72–76.
41. Fischer, T.K., Valentiner-Branth, P., Steinsland, H., Perch, M., Santos, G., Aaby, P., et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186:5 (2002), 593–597.
42. Velazquez, F.R., Matson, D.O., Calva, J.J., Guerrero, L., Morrow, A.L., Carter-Campbell, S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335:14 (1996), 1022–1028.
43. Rha, B., Tate, J.E., Payne, D.C., Cortese, M.M., Lopman, B.A., Curns, A.T., et al. Effectiveness and impact of rotavirus vaccines in the United States – 2006-2012. Expert Rev Vaccines 13:3 (2014), 365–376.
44. Cortes, J.E., Curns, A.T., Tate, J.E., Cortese, M.M., Patel, M.M., Zhou, F., et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 365:12 (2011), 1108–1117.
45. Giaquinto, C., Dominiak-Felden, G., Van Damme, P., Myint, T.T., Maldonado, Y.A., Spoulou, V., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 7:7 (2011), 734–748.
46. World Health Organisation. Rotavirus vaccines: an update. Weekly Epidemiological Record 84 (2009), 553–40.
47. Babji, S., Kang, G., Rotavirus vaccination in developing countries. Curr Opin Virol 2:4 (2012), 443–448.
48. Cooper, P.J., Chico, M.E., Losonsky, G., Sandoval, C., Espinel, I., Sridhara, R., et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 182:4 (2000), 1199–1206.
49. Uchlyama, R., Chassaing, B., Zhang, B., Gewirtz, A.T., Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J Infect Dis 210:2 (2014), 171–182.
50. Kuss, S.K., Best, G.T., Etheredge, C.A., Pruijssers, A.J., Frierson, J.M., Hooper, L.V., et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334:6053 (2011), 249–252.
51. Rod rigo, W.W., Block, O.K., Lane, C., Sukupolvi-Petty, S., Goncalvez, A.P., Johnson, S., et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 394:2 (2009), 175–182.
52. Wu, R.S., Chan, K.R., Tan, H.C., Chow, A., Allen, J.C. Jr., Ooi, E.E., Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antiviral Res 96:3 (2012), 340–343.
53. Montoya, M., Gresh, L., Mercado, J.C., Williams, K.L., Vargas, M.J., Gutierrez, G., et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis, 7(8), 2013, e2357.
54. Reich, N.G., Shrestha, S., King, A.A., Rohani, P., Lessler, J., Kalayanarooj, S., et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface, 10(86), 2013, 20130414.
55. Endy, T.P., Yoon, I.K., Mammen, M.P., Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol 338 (2010), 1–13.
56. Graham, R.R., Juffrie, M., Tan, R., Hayes, C.G., Laksono, I., Ma'roef, C., et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995–1996. Am J Trop Med Hyg 61:3 (1999), 412–419.
57. Thein, S., Aung, M.M., Shwe, T.N., Aye, M., Zaw, A., Aye, K., et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 56:5 (1997), 566–572.
58. Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:9951 (2014), 1358–1365.
59. Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:2 (2015), 113–123.
60. de Alwis, R., Bangs, D.J., Angelo, M.A., Cerpas, C., Fernando, A., Sidney, J., et al. Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype. J Virol 90:9 (2016), 4771–4779.
61. Navarro, D., Expanding role of cytomegalovirus as a human pathogen. J Med Virol 88:7 (2016), 1103–1112.
62. Baron, C., Forconi, C., Lebranchu, Y., Revisiting the effects of CMV on long-term transplant outcome. Curr Opin Organ Transplant 15:4 (2010), 492–498.
63. Modlin, J.F., Arvin, A.M., Fast, P., Myers, M., Plotkin, S., Rabinovich, R., Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis 39:2 (2004), 233–239.
64. Plorkin, S., Friedman, H., Fleisher, G., Dafoe, D., Grossman, R., Lynn Smiley, M., et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 323:8376 (1984), 528–530.
65. Plotkin, S.A., Higgins, R., Kurtz, J.B., Morris, P.J., Campbell, D.A., Shope, T.C., et al. Multicenter trial of towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:11 (1994), 1176–1178.
66. Adler, S.P., Starr, S.E., Plotkin, S.A., Hempfling, S.H., Buis, J., Manning, M.L., et al. Immunity Induced By Primary Human Cytomegalovirus Infection Protects Against Secondary Infection Among Women Of Childbearing Age. J Infect Dis 171:1 (1995), 26–32.
67. Kirchmeier, M., Fluckiger, A.C., Soare, C., Bozic, J., Ontsouka, B., Ahmed, T., et al. Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity. Clin Vaccine Immunol 21:2 (2013), 174–180.
68. Griffiths, P., Plotkin, S., Mocarski, E., Pass, R., Schleiss, M., Krause, P., et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31 (2013), B197–B203.
69. Schleiss, MR. Cytomegalovirus Vaccine Development. Current Topics in Microbiology and Immunology: Springer Science + Business Media; 2008. p. 361-82.
70. Plotkin, S., The history of vaccination against cytomegalovirus. Med Microbiol Immunol 204:3 (2015), 247–254.
71. Drysdale, S.B., Sande, C.J., Green, C.A., Pollard, A.J., RSV vaccine use – the missing data. Expert Rev Vaccines 15:2 (2016), 149–152.
72. Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A., Stewart, C.E., An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:4 (1969), 405–421.
73. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:4 (1969), 422–434.
74. Polack, F.P., Teng, M.N., Collins, P.L., Prince, G.A., Exner, M., Regele, H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196:6 (2002), 859–865.
75. Graham, B.S., Modjarrad, K., McLellan, J.S., Novel antigens for RSV vaccines. Curr Opin Immunol 35 (2015), 30–38.
76. McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:6136 (2013), 1113–1117.
77. Rappuoli, R., Bottomley, M.J., D'Oro, U., Finco, O., De Gregorio, E., Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 213:4 (2016), 469–481.
78. Jones, L.H., Recent advances in the molecular design of synthetic vaccines. Nat Chem 7:12 (2015), 952–960.
79. Mejias, A., Garcia-Maurino, C., Rodriguez-Fernandez, R., Peeples, M.E., Ramilo, O., Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine 35:3 (2017), 496–502.
80. Tregoning, J.S., Kinnear, E., Using Plasmids as DNA Vaccines for Infectious Diseases. Microbiol Spectr, 2(6), 2014.
81. Ulmer, J.B., Geall, A.J., Recent innovations in mRNA vaccines. Curr Opin Immunol 41 (2016), 18–22.
82. Goodridge, H.S., Ahmed, S.S., Curtis, N., Kollmann, T.R., Levy, O., Netea, M.G., et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 16:6 (2016), 392–400.
83. Kang, M.C., Choi, D.H., Choi, Y.W., Park, S.J., Namkoong, H., Park, K.S., et al. Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection. J Virol 90:5 (2016), 2273–2284.
84. Mallto, E., Carfi, A., Bottomley, M.J., Protein Crystallography in Vaccine Research and Development. Int J Mol Sci 16:6 (2015), 13106–13140.